- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Genelux Corporation: Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy | 1 | GlobeNewswire (USA) | ||
| 18.08. | Benchmark bestätigt Rating für Genelux Aktie nach Fortschritten bei Krebstherapie | 3 | Investing.com Deutsch | ||
| 18.08. | Benchmark reiterates Genelux stock rating on cancer therapy progress | 2 | Investing.com | ||
| 13.08. | Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates | 151 | GlobeNewswire (Europe) | -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation... ► Artikel lesen | |
| 13.08. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 30.06. | Genelux Corporation: Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi-Vec in Ovarian Cancer | 1 | GlobeNewswire (USA) | ||
| 22.06. | GENELUX Corp - 8-K, Current Report | 2 | SEC Filings | ||
| GENELUX Aktie jetzt für 0€ handeln | |||||
| 08.05. | Genelux GAAP EPS of -$0.20 | 1 | Seeking Alpha | ||
| 07.05. | GENELUX Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.03. | Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | 806 | GlobeNewswire (Europe) | -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses... ► Artikel lesen | |
| 09.01. | Weekly Buzz: ScinoPharm Gets FDA Nod; Genelux's Olvi-Vec Shows Promise; Monte Rosa Therapeutics' MRT-8102 Advances | 913 | AFX News | PARIS (dpa-AFX) - The biotech industry witnessed several key clinical trial data readouts across multiple therapeutic areas, including lung cancer, cardiovascular risk, Alzheimer's, and hepatitis.... ► Artikel lesen | |
| 02.01. | Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer | 476 | GlobeNewswire (Europe) | WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D.... ► Artikel lesen | |
| 05.11.25 | Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates | 268 | GlobeNewswire (Europe) | -- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 --... ► Artikel lesen |
13 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| INFLARX | 1,842 | +0,99 % | InflaRx NV-Aktie im Check am 20.09. (11:12 Uhr): Meine aktuelle Lageeinschätzung | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,370 | +0,85 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,385 | -2,78 % | Bis zu 2,1 Milliarden US-Dollar: Was die Exosomen-Deals von Eli Lilly und Takeda heute für NurExone bedeuten | ||
| IBIO | 1,109 | +1,46 % | iBio stock initiated at buy by H.C. Wainwright with $7 target | ||
| GERON | 1,159 | +2,79 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNITYBIO | 7,380 | -0,27 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,525 | +0,40 % | Immatics Announces $150 Million Underwritten Offering | Houston, Texas and Tuebingen, Germany, August 25, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MYRIAD GENETICS | 3,368 | 0,00 % | Myriad Genetics, Inc.: Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial | SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Vishal Sikri has been... ► Artikel lesen | |
| MANNKIND | 3,073 | 0,00 % | MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management | Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind's Technosphere- inhalation technologyMannKind to receive an equity interest and potential royalties... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,842 | -0,35 % | Ginkgo Bioworks To Build Autonomous Lab At Novo's New U.S. R&D Site In Waltham | ||
| IMMUNIC | 9,010 | -2,83 % | EQS-News: Immunic AG: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
02.09.2026 / 12:30 CET/CEST
The issuer... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,020 | +2,03 % | Emergent BioSolutions: Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility |
GENELUX CORPORATION gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,010 (-0,40 %) liegt der Kurs bei 2,520 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENELUX CORPORATION finden Sie auf Wallstreet Online.